Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL

Inclusion Criteria: * B-CLL (CD23+, CD5+, CD19+, CD20+) * Treatment indication according to NCI criteria * Age \>= 18 yrs * No previous treatment of CLL by chemo-, radio- or immunotherapy * Life expectancy \> 6 months * Written informed consent * Women of non-childbearing potential or women of childbearing potential and men using effective contraception Exclusion Criteria: * Active bacterial, viral or fungal infection * Positivity for HIV, Hepatitis B or C * Reduce organ functions and bone marrow dysfunction not due to CLL * Creatinine clearance below 30 ml/min * Patients with medical conditions requiring long-term use of systemic corticosteroids during study treatment * Patients with a history of severe cardiac disease * Other known co-morbidity with the potential to dominate survival * Transformation to aggressive B-cell malignancy * Known hypersensitivity to humanised monoclonal antibodies or any of the study drugs * Pregnant or breast-feeding women * Any co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent